Exonhit Buying InGen for $23.1M, Creating New Dx Firm Diaxonhit | GenomeWeb

NEW YORK (GenomeWeb News) – French biotech firm Exonhit announced today an agreement to acquire InGen BioSciences for €18 million ($23.1 million), forming a new firm called Diaxonhit.

Exonhit will pay €8 million in cash as part of the deal, with the balance to be paid in Exonhit stock to shareholders of InGen. The deal is anticipated to close next month, pending approval by Exonhit shareholders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.